Search results
Showing 76 to 90 of 2128 results for technology appraisal
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]
In development Reference number: GID-TA10832 Expected publication date: TBC
Awaiting development Reference number: GID-TA10519 Expected publication date: TBC
Upadacitinib for treating severe rheumatoid arthritis (TA665)
Evidence-based recommendations on upadacitinib (Rinvoq) for severe active rheumatoid arthritis in adults.
Guidance on the use of electroconvulsive therapy: review proposal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 February 2026.
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]
In development Reference number: GID-TA10497 Expected publication date: TBC
In development Reference number: GID-TA11201 Expected publication date: 26 February 2026
Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.
View recommendations for TA274Show all sections
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults.
Adalimumab for treating moderate to severe plaque psoriasis (TA146)
Evidence-based recommendations on adalimumab (Humira) for treating psoriasis in adults.
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.
This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.
NICE is unable to make a recommendation on tisagenlecleucel (Kymriah) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies. This is because Novartis did not provide a complete evidence submission.
Show all sections
Sections for TA933
NICE is unable to recommend panitumumab with 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) for previously treated metastatic colorectal cancer in adults. This is because Amgen did not provide an evidence submission.
Show all sections
Sections for TA240